Functional and Morphological Changes in Diabetic Macular Oedema: Baseline Correlations, and Changes with Pharmacological Treatments Volume 3 - Issue 1

Saker Saker*, Marco U Morales, Furat Raslan, Craig Wilde and Winfried M Amoaku

• Department of Ophthalmology, University of Nottingham, United Kingdom

Received:February 11, 2021;   Published:March 8, 2021

Corresponding author: Saker Saker, Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Queen’s Medical Centre, Nottingham, NG7 2UH, United Kingdom.

DOI: 10.32474/TOOAJ.2021.03.000159

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Several pharmacologic agents are now available for the treatment of DMO including anti-VEGF agents [1-6] and corticosteroids [1-11]. The introduction and frequency of these treatments has coincided with the introduction of less invasive investigating and monitoring systems including OCT [12-17] and fundus related perimetry, also known as microperimetry (MP) [18, 23]. OCT is now well established in the evaluation of DMO, especially with the recent advances with spectral domain models [1-27]. It has contributed significantly to our understanding of the anatomical changes of DMO and the intra-retinal damage and provides a valuable tool for the follow-up of macular oedema [14]

Introduction| Methods| Results| Discussion| References|